Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Consumer Health North America Head Piergallini To Lead Worldwide

This article was originally published in The Tan Sheet

Executive Summary

Novartis Consumer Health North America head Al Piergallini will take over as head of Consumer Health worldwide, succeeding Thomas Ebeling, who has been named worldwide chief operating officer of pharmaceuticals under division CEO Jerry Karabelas. Piergallini will continue to lead North America as well; a replacement will not be sought immediately, the company said.

You may also be interested in...



Novartis Launching Lamisil AT With $20 Mil. TV/Print Ad Campaign

Novartis plans to spend $20 mil. on TV and print advertising in 1999 to launch Lamisil AT, the firm's new OTC athlete's foot medication. An Rx-to-OTC switch of the 1% terbinafine cream was approved by FDA March 9 ("The Tan Sheet" March 15, p. 11).

Novartis Lamisil AT OTC Antifungal Said To Work In One Week

Novartis said its new OTC athlete's foot medication Lamisil AT Cream is the only nonprescription medication that cures athlete's foot with one week of treatment in its announcement that FDA has approved the Rx-to-OTC switch.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS090647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel